Today's guest post comes from Megan Wetzel, Vice President of Product, Access and Affordability at CoverMyMeds. Megan examines how prior authorization execution has become a strategic differentiator for biopharma brands as formulary changes and expanding utilization management put more pressure on access. She argues that building consistent, scalable prior auth execution can reduce therapy delays, improve determination time, and strengthen brand performance across the product lifecycle. To learn more about CoverMyMeds' prior authorization solution, download their case study: From Decline to Growth: How One Brand Expanded Access in Late Lifecycle . Read on for Megan's insights. Read more » ©…
Today's guest post comes from Megan Wetzel, Vice President of Product, Access and Affordability at CoverMyMeds.
Megan examines how prior authorization execution has become a strategic differentiator for biopharma brands as formulary changes and expanding utilization management put more pressure on access. She argues that building consistent, scalable prior auth execution can reduce therapy delays, improve determination time, and strengthen brand performance across the product lifecycle.
To learn more about CoverMyMeds' prior authorization solution, download their case study:
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle.
Read on for Megan's insights.
Read more »
US Pharma Marketing
